The company's lead product candidate, CR845, is a potent peripheral kappa opioid receptor agonist that has shown efficacy in treating moderate-to-severe pain and itch without the typical side effects associated with other therapeutics. Cara also has a product called Korsuva, which is being studied for acute pain, chronic pain, and uremic pruritus. Additionally, Cara is developing a pipeline of first-in-class molecules using its proprietary drug screening technology to target novel analgesic and anti-inflammatory features.